Cowen and Company affirms its Market Perform rating on Gevo.
Cowen and Company affirms its Market Perform rating and $1.35 target price on Gevo, Inc. (Nasdaq: GEVO) following quarterly results issued Tuesday night.
As a refresher, Gevo reported Q4 loss of $0.35 per share and revs of $1.7 million from Street consensus calling for a loss of $0.34 per share and revs of $1.46 million.
Cowen analyst Robert Stone noted, “Luverne is shifting to concurrent production of ethanol and isobutanol, to take advantage of current wide ethanol spreads. The initial mix will be three fermenters producing ethanol, one producing isobutanol. We believe this demonstrates the flexibility of the GEVO technology, and highlights successful isolation and eradication of sources of infection. It may have been influential in attracting the two licensing LOIs signed since October.”
Bottom line: “The economics now favor, and the science now enables, concurrent production of isobutanol and ethanol at Luverne. However, we believe ramping to full nameplate, regardless of configuration, is still at least several quarters away.”
For an analyst ratings summary and ratings history on Gevo, Inc. click here. For more ratings news on Gevo, Inc. click here.